Evidence map›Paper›PMID 39006384›Full record

ReviewWorld journal of gastroenterology2024

Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease.

Jeffrey A Lowell, Michael J Farber, Keith Sultan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeffrey A LowellDepartment of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, NY 11030, United States. jlowell@northwell.edu.
Michael J FarberPreclinical Studies, New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY 11545, United States.
Keith SultanDivision of Gastroenterology, Northwell Health, North Shore University Hospital and Long Island Jewish Medical Center, Great Neck, NY 10021, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is entering a potentially new era of combined therapeutics. Triantafillidis

Indexed as

Biological ProductsDrug Therapy, CombinationInflammatory Bowel DiseasesHumansImmunomodulating AgentsRandomized Controlled Trials as TopicTreatment OutcomeBiological ProductsImmunomodulating AgentsBiologicsCombination therapyDual-therapyImmunomodulatorsInflammatory bowel disease

Identifiers

PMID39006384
PMCPMC11238668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.